.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Julphar
Baxter
Moodys
Chubb
UBS
Johnson and Johnson
Dow
Citi
McKinsey

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090549

« Back to Dashboard
NDA 090549 describes PENICILLIN V POTASSIUM, which is a drug marketed by Ivax Sub Teva Pharms, Mylan, Am Antibiotics, Aurobindo Pharma, Dava Pharms Inc, Hikma Pharms, Purepac Pharm, and Sandoz, and is included in thirteen NDAs. It is available from twenty-five suppliers. Additional details are available on the PENICILLIN V POTASSIUM profile page.

The generic ingredient in PENICILLIN V POTASSIUM is penicillin v potassium. There are eighty-seven drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the penicillin v potassium profile page.

Summary for 090549

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 090549

Ingredient-typePenicillins

Suppliers and Packaging for NDA: 090549

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PENICILLIN V POTASSIUM
penicillin v potassium
TABLET;ORAL 090549 ANDA West-Ward Pharmaceuticals Corp 0143-9836 0143-9836-01 100 TABLET, FILM COATED in 1 BOTTLE (0143-9836-01)
PENICILLIN V POTASSIUM
penicillin v potassium
TABLET;ORAL 090549 ANDA West-Ward Pharmaceuticals Corp 0143-9836 0143-9836-10 1000 TABLET, FILM COATED in 1 BOTTLE (0143-9836-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 250MG BASE
Approval Date:Oct 11, 2013TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 500MG BASE
Approval Date:Oct 11, 2013TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
Cerilliant
Argus Health
Daiichi Sankyo
Moodys
Julphar
Johnson and Johnson
McKinsey
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot